Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation

Chinese PLA General Hospital10 enrolled

Overview

This is a randomized ,opened, prospective controlled trial of clinical effectiveness for Icotinib as the adjunctive treatment after surgery in stage I-IIIB lung adenocarcinoma patients with epidermal growth factor receptor gene mutation

In this trial the investigators will enlist 100 patients who accepted surgery and with epidermal growth factor receptor gene mutation,these patients will be divided into 2 groups (chemotherapy group and Icotinib group),compare the PFS,RFS,OS after 5 years follow up

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Neoplasms, Therapy-Associated

Interventions

IcotinibDRUG

compared with chemotherapy,which is better for lung adenocarcinoma patients with epidermal growth factor receptor gene mutation after surgery

chemotherapy (Carboplatin and Docetaxel)DRUG

as control group,compared with Icotinib

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18-75 years old * Lung adenocarcinoma patients with epidermal growth factor receptor gene mutation,stage I-IIIB after surgery * The patients' Eastern Cooperative Oncology Group scores are ≤ 0-2 Exclusion Criteria: * Mismatch conditions above * Have used other anti-cancer therapy drug before the trial and may influence the outcome

Locations (1)

PLA General Hospital

Beijing, China

Outcomes

Primary Outcomes

Recurrence-free Survival

Time frame: 6 months

Secondary Outcomes

Overall survival

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.